Oxytocin antagonist [1-D(CH2)5,Tyr(ME)2,Thr4,Tyr-NH2(9)]ornithine vasotocin inhibits oxytocin-induced prostaglandin F2alpha release in late-pregnant cows.
The affinity and specificity of an antagonist of oxytocin, [1-D(CH2)5,Tyr(ME)2,Thr4,Tyr-NH2(9)]ornithine vasotocin (OTA), to oxytocin receptors (OTR) in bovine gestational endometrium was determined in displacement experiments with oxytocin (OT) and vasopressin (AVP) analogues and compared to myometrial OTR. OTA had the highest affinity in both tissues. The effect of OTA on OT-induced increase in plasma concentration of 13,14-dihydro-15-keto-prostaglandin F2alpha metabolite (PGFM) was studied in 24 late-pregnant cows. Treatments consisted of i.v. saline; OT (50 IU); OTA (1200 microg); and OTA (400, 1200, or 4000 microg) injected i.v. 5 min before OT (50 IU) (n = 4 each). Samples were collected from jugular vein at 15-min intervals for 30 min before and 3 h after the injection of OT. Progesterone was measured in once-daily samples taken for 7 days after the experiment. OT caused a twofold increase in plasma PGFM within about 60 min (p < 0.005), with levels returning to baseline at 150-180 min; OTA (1200 microg) caused a gradual lowering of basal plasma PGFM over 180 min (p < 0.05). The 400-microg or 1200-microg dose of OTA did not alter OT-induced PGFM response, whereas the 4000-microg dose inhibited it almost completely (p < 0.005). Plasma progesterone declined after the experiment in all cows, with no differences among groups. Because OTA inhibits OT-induced release of endometrial prostaglandin F2alpha it may be a good tocolytic agent.
Fuchs
A R
AR
Department of Obstetrics and Gynecology, Cornell University Medical College, New York, New York 10021, USA. annariitta@aol.com
Fields
M J
MJ
Chang
S M
SM
Thatcher
W W
WW
Willard
C C
CC
Randel
R D
RD
D000818:Animals; D002417:Cattle / Q000502:physiology*; D002462:Cell Membrane / Q000378:metabolism; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism*; D004717:Endometrium / Q000378:metabolism; D005260:Female; D007700:Kinetics; D009215:Myometrium / Q000378:metabolism; D010121:Oxytocin / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D018045:Receptors, Oxytocin / Q000378:metabolism; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
D018045:Receptors, Oxytocin; C076093:vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-O-methyl-Tyr(2)-Thr(4)-Orn(8)-Tyr(9)-NH2; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost; D014668:Vasotocin